Early Treatment Benefits Some Children With Retinopathy of Prematurity

Beaumont Participates in Research Study Announced Today in Archives of Ophthalmology 

CHICAGO– Certain children with the visual condition known as retinopathy of prematurity appear to see better at age 6 if they received treatment early, whereas others benefit more from observation than early treatment, according to a report posted online today that will appear in the June print issue of Archives of Ophthalmology, one of the Journal of the American Medical Association/Archives journals. 

Beaumont vitreo-retinal specialist, Antonio Capone, M.D.

Retinopathy of prematurity occurs in babies born early; abnormal blood vessels and scar tissue grow over the retina, decreasing vision. A previous study on retinopathy of prematurity helped researchers identify two types of the condition—Type 1 and Type 2—based on various clinical characteristics, according to background information in the article. Differences between the two include stage of disease, area of the retina affected and the presence or absence of plus disease (severe growth of additional blood vessels in the back of the eye). 

In the previous study of 401 infants whose eyes were randomly assigned to early treatment or conventional management, early treatment appeared to show a benefit at 9 months. The Early Treatment for Retinopathy of Prematurity Cooperative Group followed the same group of children through 6 years of age (370 had survived).

Overall, early treatment was not associated with improved vision at 6 years. However, eyes of children with Type 1 retinopathy of prematurity appeared to have improved vision at age 6 if they were treated early (25.1 percent vs. 32.8 percent had an unfavorable outcome). There did not appear to be a benefit of early treatment for eyes of children with Type 2 retinopathy at age 6 (23.6 percent vs. 19.4 percent unfavorable outcomes). 

In the original nine-month study,“the analysis identified eyes with characteristics indicating a benefit for early treatment (Type 1) and eyes that could be observed (Type 2), with treatment offered if the disease progressed to Type 1,” the authors write.“These divisions into Type 1 and Type 2 eyes were not preplanned as part of the original design in 1999 but came about in 2003 as a result of analysis of initial study outcome data. There was an obligation to follow these eyes according to this subdivision once the types had been developed and published.” 

The results demonstrate that the benefit of treatment for children with Type 1 disease lasts as long as six years, they note.“Visual acuity is improved with early treatment, but nevertheless, 65.4 percent of eyes receiving early treatment develop visual acuity worse than 20/40. Whether this result is due to retinal, cortical or both factors remains to be determined, but clearly prevention of retinopathy of prematurity now assumes an even higher priority since early treatment is beneficial for some eyes but often does not result in normal development of visual acuity.”

(Arch Ophthalmol. 2010;128[6]:(doi:10.1001/archophthalmol.2010.72).   

Editor’s Note: This work was supported by cooperative agreements with the National Eye Institute of the National Institutes of Health,U.S. Departments of Health and Human Services, Bethesda, Md.  

The National Eye Institute, part of the National Institutes of Health, leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments.

The National Institutes of Health (NIH)— The Nation's Medical Research Agency— includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.